Transcription profiling of human rapamycin treated of MDA-MB-468 breast cancer cell line and MDA-MB-468 xenografts

ABSTRACT: Mammalian target of rapamycin (mTOR) is a serine/threonine kinase involved in multiple intracellular signaling pathways promoting tumor growth. mTOR is aberrantly activated in a significant portion of breast cancers and is a promising target for treatment. Rapamycin and its analogues are in clinical trials for breast cancer treatment. Patterns of gene expression (metagenes) may also be used to simulate a biologic process of effects of a drug treatment. In this study, we tested the hypothesis that the gene-expression signature regulated by rapamycin could predict disease outcome for patients with breast cancer. Results: Colony formation and sulforhodamine B (IC50 < 1nM) assays, and xenograft animals showed that MDA-MB-468 cells were sensitive to treatment with rapamycin. The comparison of i

ORGANISM(S): Homo sapiens

SUBMITTER: Funda Meric-Bernstam 

PROVIDER: E-GEOD-18571 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress